Neoadjuvant Olaparib Plus Carboplatin Reduces Residual Cancer Burden in BRCA1/2-Mutated, HRD+ TNBC - OncLive

Neoadjuvant Olaparib Plus Carboplatin Reduces Residual Cancer Burden in BRCA1/2-Mutated, HRD+ TNBC  OncLive ...

Neoadjuvant,Olaparib,Plus,Carboplatin,Reduces,Residual,Cancer,Burden,in,BRCA1/2-Mutated